The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington’s Disease

The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington’s Disease

SRX246, an orally available CNS penetrant vasopressin (VP) V1a receptor antagonist, was studied in Huntington’s disease (HD) patients with irritability and aggressive behavior in the exploratory phase 2 trial, Safety, Tolerability, and Activity of SRX246 in Irritable HD patients (STAIR). This was a...

Full description

Bibliographic Details
Main Authors: Hilda T. Maibach, Michael J. Brownstein, Steven M. Hersch, Karen E. Anderson, Debra E. Itzkowitz, Eve M. Damiano, Neal G. Simon
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Journal of Personalized Medicine
Subjects:
Huntington’s disease
vasopressin 1a receptor antagonist
irritability
aggression
Online Access:https://www.mdpi.com/2075-4426/12/10/1561

Internet

https://www.mdpi.com/2075-4426/12/10/1561

Similar Items